JPMorgan Chase & Co. Cuts Waystar (NASDAQ:WAY) Price Target to $38.00

Waystar (NASDAQ:WAY) had its target price reduced by JPMorgan Chase & Co. from $40.00 to $38.00 in a report released on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 77.74% from the stock’s current price.

Several other brokerages also recently commented on WAY. Evercore set a $27.00 price objective on shares of Waystar in a research report on Wednesday, February 18th. Wall Street Zen downgraded shares of Waystar from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Truist Financial reduced their price objective on shares of Waystar from $51.00 to $38.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Leerink Partners started coverage on shares of Waystar in a research report on Monday, February 2nd. They set an “outperform” rating and a $43.00 price objective for the company. Finally, UBS Group reduced their price objective on shares of Waystar from $41.00 to $37.00 and set a “buy” rating for the company in a research report on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.38.

Waystar Trading Down 15.4%

NASDAQ WAY traded down $3.89 during trading hours on Thursday, hitting $21.38. 8,044,196 shares of the company’s stock were exchanged, compared to its average volume of 2,638,253. The stock has a 50-day simple moving average of $24.65 and a 200 day simple moving average of $29.80. Waystar has a 1-year low of $20.35 and a 1-year high of $42.55. The firm has a market cap of $4.10 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 1.00 and a beta of 0.87. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.38.

Waystar (NASDAQ:WAY) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.39 by $0.03. The company had revenue of $313.87 million during the quarter, compared to the consensus estimate of $311.72 million. Waystar had a net margin of 10.20% and a return on equity of 6.86%. The company’s quarterly revenue was up 22.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 EPS. Waystar has set its FY 2026 guidance at 1.590-1.680 EPS. On average, equities analysts forecast that Waystar will post 1.46 EPS for the current fiscal year.

Institutional Trading of Waystar

Several hedge funds have recently bought and sold shares of WAY. Salomon & Ludwin LLC acquired a new stake in Waystar in the 3rd quarter valued at $25,000. Root Financial Partners LLC grew its position in Waystar by 6,475.0% in the 1st quarter. Root Financial Partners LLC now owns 1,052 shares of the company’s stock valued at $25,000 after purchasing an additional 1,036 shares during the period. ANTIPODES PARTNERS Ltd grew its position in Waystar by 120.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 823 shares of the company’s stock valued at $31,000 after purchasing an additional 449 shares during the period. First Horizon Corp acquired a new stake in Waystar in the 3rd quarter valued at $38,000. Finally, Smartleaf Asset Management LLC grew its position in Waystar by 6,005.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,160 shares of the company’s stock valued at $38,000 after purchasing an additional 1,141 shares during the period.

Key Stories Impacting Waystar

Here are the key news stories impacting Waystar this week:

• Positive Sentiment: Q1 beat on both EPS and revenue, with revenue up ~22% YoY and healthy margins (adjusted EBITDA margin ~43%), showing solid underlying demand and profitability. Waystar Reports First Quarter 2026 Results
• Positive Sentiment: Needham reaffirmed its Buy rating and set a $33 price target, signaling confidence in Waystar’s longer-term thesis and suggesting meaningful upside from current levels. Needham Reaffirms Buy, $33 PT
• Neutral Sentiment: Full Q1 earnings call transcript and company disclosures are available for details on revenue mix, churn, and product cadence — useful for investors who want to dig into the management commentary behind the guidance shift. Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst write-ups (Zacks/MarketBeat) note the beats and provide metric-level context; these analyses flag the company’s strong margin profile while highlighting investor focus on forward guidance. Waystar Reports Q1 Earnings: What Key Metrics Have to Say
• Neutral Sentiment: Coverage of Waystar’s new AltitudeAI tools suggests potential upside to data/moat and margins over time, but benefits are speculative and unlikely to offset near-term guidance concerns. Could Waystar’s New AltitudeAI Tools Quietly Redefine Its Data Moat And Margins Narrative (WAY)?
• Negative Sentiment: Management set 2026 revenue guidance of roughly $1.274B–$1.294B and shifted expected Q2 sequential growth to flat or down ~1%, signaling slower near-term cadence than some investors hoped; that cautious outlook is the main catalyst for the stock decline. Waystar signals 2026 revenue of $1.274B-$1.294B while shifting Q2 sequential growth to flat-1%

About Waystar

Waystar (NASDAQ:WAY) is a leading provider of cloud-based revenue cycle management and payment solutions for healthcare organizations. The company’s unified platform streamlines the entire financial continuum of patient care, from eligibility verification and claim submission to payment reconciliation and patient billing. By automating key processes and improving claim accuracy, Waystar helps providers reduce administrative overhead, accelerate cash flow and enhance overall revenue performance.

At the core of Waystar’s offering is a SaaS-based architecture that integrates seamlessly with existing electronic health record (EHR) systems and payer networks.